Ligand Pharmaceuticals Inc. | Mid-cap | Healthcare

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 167.1M
Gross Profit 156.1M 93.37%
Operating Income 23.0M 13.77%
Net Income -4.0M -2.41%
EPS (Diluted) -$0.22

Balance Sheet Metrics

Total Assets 941.8M
Total Liabilities 111.3M
Shareholders Equity 830.4M
Debt to Equity 0.13

Cash Flow Metrics

Operating Cash Flow 68.7M
Free Cash Flow 77.4M

Revenue & Profitability Trend

Ligand Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue167.1M131.3M196.2M241.5M163.6M
Cost of Goods Sold11.1M10.5M52.8M62.2M30.4M
Gross Profit156.1M120.8M143.4M179.4M133.1M
Operating Expenses100.1M77.3M106.1M41.3M101.1M
Operating Income23.0M9.8M3.0M103.9M20.4M
Pre-tax Income2.5M63.7M36.0M72.2M1.3M
Income Tax6.6M9.8M41.2M-4.1M-5.3M
Net Income-4.0M52.2M-33.4M57.1M-3.0M
EPS (Diluted)-$0.22$2.94-$1.98$3.34-$0.18

Income Statement Trend

Ligand Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets331.6M237.4M263.6M464.8M500.6M
Non-Current Assets610.2M549.8M499.1M832.8M861.7M
Total Assets941.8M787.2M762.7M1.3B1.4B
Liabilities
Current Liabilities37.1M16.8M98.8M41.7M100.1M
Non-Current Liabilities74.2M69.5M66.4M434.8M552.6M
Total Liabilities111.3M86.3M165.2M476.4M652.8M
Equity
Total Shareholders Equity830.4M700.9M597.5M821.2M709.5M

Balance Sheet Composition

Ligand Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-4.0M52.2M-33.4M57.1M-3.0M
Operating Cash Flow68.7M93.3M170.6M67.4M50.8M
Investing Activities
Capital Expenditures-1.8M-3.5M-17.9M-8.8M-4.5M
Investing Cash Flow-133.3M38.2M163.5M30.0M230.3M
Financing Activities
Dividends Paid-----
Financing Cash Flow31.6M-82.4M-279.2M-171.5M-313.6M
Free Cash Flow77.4M-4.3M119.9M70.0M50.1M

Cash Flow Trend

Ligand Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 46.27
Forward P/E 19.31
Price to Book 2.80
Price to Sales 12.28
PEG Ratio 19.31

Profitability Ratios

Profit Margin -73.07%
Operating Margin -80.87%
Return on Equity -16.56%
Return on Assets -1.14%

Financial Health

Current Ratio 5.27
Debt to Equity 0.56
Beta 0.71

Per Share Data

EPS (TTM) -$7.29
Book Value per Share $41.27
Revenue per Share $9.73

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
lgnd2.2B46.272.80-16.56%-73.07%0.56
Vertex 124.2B32.827.53-5.64%-8.91%10.00
Regeneron 59.1B13.921.9715.96%31.94%9.20
Blueprint Medicines 8.3B-120.1424.23-47.71%-27.70%208.50
Roivant Sciences 7.4B1.951.61-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.